anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The investogators prescribed curcuminoids 1,500 mg/day . The regimen was curcuminoids 500 mg three times a day from three days before the procedure until two days after. All patients also received standard prophylaxis protocol which included 0.9% sodium chloride 1 mL/kg/hour, given 12 hours before and 12 hours after CAG unless contraindicated.
The present invention relates to a composition for maintaining a weak acidic virginal environment. The composition for maintaining a weak acidic virginal environment according to the present invention allows virginal lubrication and moisturization in a weak acidic environment and releases an organic acid in an alkaline environment, depending on a change in virginal acidity of women, thereby changing a virginal environment into a weak acidic environment. The composition according to the present invention includes 100-1,000 parts by weight of a hydrogel formed from 0.1-10 parts by weight of an organic acid, 0.1-20 parts by weight of a pH-dependent polymer which is dissolved when the virginal acidity of a woman is pH 4.5 or higher to release an organic acid present therein, 0.1-50 parts by weight of an antifungal agent, and the balance amount of water. Therefore, when the virginal pH environment is weak acidic, the composition is released while providing lubrication and moisturizing functions. In addition, the composition is converted into an adhesive gel in a neutral environment to maintain an acidic environment for a long time and to provide an antibacterial and anti-inflammatory functions. Further, in an alkaline environment, the composition rapidly releases the organic acid and discharges virginal foreign materials. Therefore, the composition can be used for monitoring and early diagnosis of a virginal environment.
PURPOSE:To provide a depilatory sheet material composed of a depilatory agent and a polymer base which can be activated with water, having excellent workability in use, quantitatively applicable to the part to be depilated, containing the depilatory agent in stable form and capable of beautifully depilating the hair from the skin. CONSTITUTION:The objective depilatory sheet material contains (A) a depilatory agent exhibiting depilatory action preferably in the presence of water, e.g. thioglycolic acid or its salt, etc., and (B) a water-sensitive polymer base exhibiting pressure-sensitive adhesivity when brought into contact with water, e.g. polyvinyl pyrrolidone, etc. The amounts of A and B in the material are 1-15wt% and 85-99wt%, especially 3-12wt% and 88-97wt%, respectively. The depilatory material can be applied simply by wetting the application surface with water and applying to the skin to be depilated. The polymer base becomes pressure-sensitive adhesive and the drug component is dissolved and brought into contact with the hair by this procedure to effect the depilation. Since the drug component is delivered at a prescribed rate, the material has excellent depilation processability. The age stability of a depilatory unstable to water can be improved because the material is brought into contact with water in use.
The invention discloses an mRNA vaccine for preventing or treating tumors and application thereof, and relates to the technical field of biology. The mRNA expression cassette includes a gene coding region encoding a PD-1 antigen; the nucleotide sequence of the coding region of the gene for encoding the PD-1 antigen is shown as SEQ ID NO. 1. The mRNA vaccine provided by the invention can inhibit the combination of PD-1 and PD-L1, inhibit immune escape, up-regulate cytokines and chemotactic immune cells to infiltrate into the tumor microenvironment, thereby playing a role in enhancing the killing of the immune cells to tumors. In a PD-1 humanized mouse primary liver cancer model, the therapeutic effect is more excellent than that of the Nawu antibody, and the medicine is expected to be a solid tumor therapeutic medicine which can replace PD-1 monoclonal antibody medicine and has great potential. In addition, the invention also provides a combined therapeutic drug of the mRNA vaccine and other drugs such as monoclonal antibodies. Has more excellent treatment effect than the combination of the Nawuzumab and the Avastin monoclonal antibody.
Hydroxylated nebivolol metabolites increase NO release from human endothelial cell preparations in a concentration dependent fashion following acute administration. In addition, hydroxylated nebivolol metabolites, including but not limited to 4-hydroxy-6,6′difluoro-, 4-hydroxy-5-phenol-6,6′difluoro-, and 4-hydroxy-8-pheno-6,6′difluoro-, have the ability to increase the capacity for NO release in human endothelial cells following chronic administration. This invention provides hydroxylated nebivolol metabolites and compositions comprising nebivolol and/or at least one hydroxylated metabolite of nebivolol and/or at least one additional compound used to treat cardiovascular diseases or a pharmaceutically acceptable salt thereof. In addition, this invention provides methods of treating and/or preventing vascular diseases by administering at least one hydroxylated metabolite of nebivolol that is capable of releasing a therapeutically effective amount of nitric oxide to a targeted site affected by the vascular disease. Also, this invention is directed to the treatment and/or prevention of migraine headaches administering at least one hydroxylated metabolite of nebivolol. This invention may also be used in conjunction with or as a single treatment of metabolic syndrome disorders.
OBJECTIVE: One of the most frequently discussed physical parameters in juvenile idiopathic arthritis (JIA) is physical activity level. There is limited evidence about determinants of physical activity level in JIA. In this study, we aimed to investigate the determinants of physical activity level in children and adolescents with JIA.
MATERIALS AND METHODS: Thirty-two JIA patients and 18 age- and sex-matched healthy individuals were included in the study. The age range was 8-18 years. Sociodemographic and clinical data of the participants were recorded. In both groups, anthropometry, fatigue, pain, knee extension muscle strength, gait variables, functional exercise capacity assessed by six-minute walk test (6MWT), and arterial stiffness were evaluated. Physical activity level was assessed by an accelerometer.
RESULTS: The disease activity level of the patients was low. Pain and fatigue scores were significantly higher in the JIA group compared to healthy controls (p < 0.05). Walking speed, physical activity level, time spent in low-intensity physical activity, time spent in moderate-to-vigorous-intensity physical activity, and 6MWT distance were significantly lower than in healthy controls (p < 0.05). Quadriceps muscle strength and arterial stiffness assessment results were similar in both groups (p > 0.05). In the JIA group, there was a positive correlation between physical activity and age, height, fat-free body mass, quadriceps muscle strength, and 6MWT distance (p < 0.05). Also, there was a negative correlation between physical activity and pain, fatigue, and cadence. Physical activity level was independently associated with 6MWT distance (42.9% of the variability).
CONCLUSION: In mildly affected JIA patients, gait speed, functional exercise capacity, and physical activity level are affected. Functional exercise capacity is a determinant of physical activity level in JIA.
Even the invasive treatment of coronaropathy during hospitalization, with angioplasty and stent implantation procedures and/or the eventual implantation of temporary mechanical blood circulation assistant devices \[aortic counterpulsation, Impella, ECMO (Extracorporeal Membrane Oxygenation)\], could further favour the phenomenon. Vice versa, thrombocytosis occurring during ACS has a reactive origin, caused by increased IL-6 production which, in turn, leads to an increase in thrombopoietin formation in the liver, causing a consequent stimulatory activity on megakaryocytes. Different studies have demonstrated a significant correlation between platelets count disorders and patient outcome (survival during hospitalization and in the immediate follow-up). This association has, however, often been considered an epiphenomenon of the underlying pathology. Platelets count alterations are, indeed, usually consensual to other hemogram alterations (anaemia and neutropenia), an indication of a coexisting medullar insufficiency (thrombocytopenia) or other heterogenous diseases such as cancer, iron deficiency or immuno-modulated diseases, usually associated with an increase in comorbidity indexes. Those alterations, moreover, can usually influence changes to the therapeutic approach (reduction/suspension of recommended standard therapies) and further condition the prognosis. Since a few years,the investigators have been established a cardiac-haematological collaboration aiming at finding early alterations in platelets count or, more generally, in cell blood count (CBC), collegially evaluating those alterations with a cardiologist and a haematologist (even in mild cases) and scheduling, on the basis of the aforementioned evaluations, a more precise and tailored therapeutic approach toward the specific patient needs in order to minimize the downgrading of potentially life-saving therapies. Until now, however, no precise evaluation of the impact that this strategy had in influencing the therapeutic approach and in improving patient outcome in our population has been performed.

A retrospective evaluation of consecutive ACS patients, their clinical, biohumoral and procedural characteristics and the adopted pharmacological treatments is, therefore, an important epidemiologic tool for the characterization of this phenomenon and for identifying potential associations which could suggest possible future therapeutic developments.
The treatment group will be given the following assessments at baseline and four weeks post-randomization: the Patient Health Questionnaire (PHQ-9), Generalized Anxiety Disorder 7-item scale (GAD-7), Cambridge Brain Sciences (CBS) tasks, and the COVID-19 Persistent Symptom Questionnaire. The principal investigator will schedule two Biosound Therapy sessions per week for four weeks for all treatment group participants. The treatment sessions will not occur on consecutive days. All participants in the treatment group will listen to identical playlists. At the beginning of the BTS session, the participant will complete a session of HeartMath biofeedback. Next, the participant will receive approximately 30-40 minutes of music containing binaural beats synchronized with sound massage.The session will finish with gratitude-based video content.
Acute necrotizing pancreatitis (ANP) is lethal complication and account for 10-20% of total pancreatitis. Necrotic collection is seen in majority of ANP and \>50% of necrotic collection transform into Walled of necrosis (WON). Management of WON is challenging and under progressive evolution. With the advent of "step up approach" WON is effectively managed with greater success. Various studies and meta-analysis proved the efficacy of dedicated self-expandable metal stents (SEMS) over plastic stent in WON management. Disconnected pancreatic duct syndrome (DPDS) is late complication of necrotizing pancreatitis and increasingly identified after necrosectomy. DPDS is defined as complete disruption of the main pancreatic duct, resulting in a variable portion of the upstream pancreatic gland becoming isolated from the main pancreatic duct downstream. Ductal disruption leads to accumulation of pancreatic juice forming pancreatic or peri-pancreatic fluid collection. Incidence of recurrence of PFC in DPD is \~ 50%. DPDS is a separate clinical entity which demands special strategic approach and requires frequent re-intervention (surgical/endoscopic). Treatment option for DPDS is controversial and not yet clearly defined. Studies have shown that long term transmural plastic stent placement can reduce the recurrence rate (Stent removed-17% vs stent left behind-1.7%). So, some experts recommend that transmural stents can be left in situ indefinitely to decrease recurrence of PFC. Nowadays, SEMS are widely used for management of WON. However, metal stents cannot be kept for longer period because of increasing adverse events associated with longer duration (impaction/burring of SEMS in gastric wall, bleeding). So, recommendation is to remove SEMS as early as possible (within 4-6 weeks of drainage). Considering this fact, study is planned to evaluate the effect of transmural plastic stenting on recurrence of PFC after SEMS removal in walled off necrosis with DPDS. This will be randomised control study in patients with WON with DPDS who underwent SEMS drainage. After removal of SEMS patients with documented DPDS (magnetic resonance pancreatography and endoscopic retrograde pancreatography) will be randomised into 2 arms. In study arm after SEMS removal transmural plastic stent will be placed in to the cavity and in control arm SEMS will be removed with no transmural stenting. Thereafter patients will be followed at 3 months,6 months and yearly.
Cancer cachexia is an involuntary loss of body weight, mostly of skeletal muscle. Previous research favors the existence of a microbiota-muscle crosstalk, so the aim of the study was to evaluate the impact of microbiota alterations induced by antibiotics on skeletal muscle proteins expression. Skeletal muscle proteome changes were investigated in control (CT) or C26 cachectic mice (C26) with or without antibiotic treatment (CT-ATB or C26-ATB, n = 8 per group). Muscle protein extracts were divided into a sarcoplasmic and myofibrillar fraction and then underwent label-free liquid chromatography separation, mass spectrometry analysis, Mascot protein identification, and METASCAPE platform data analysis. In C26 mice, the atrogen mafbx expression was 353% higher than CT mice and 42.3% higher than C26-ATB mice. No effect on the muscle protein synthesis was observed. Proteomic analyses revealed a strong effect of antibiotics on skeletal muscle proteome outside of cachexia, with adaptative processes involved in protein folding, growth, energy metabolism, and muscle contraction. In C26-ATB mice, proteome adaptations observed in CT-ATB mice were blunted. Differentially expressed proteins were involved in other processes like glucose metabolism, oxidative stress response, and proteolysis. This study confirms the existence of a microbiota-muscle axis, with a muscle response after antibiotics that varies depending on whether cachexia is present.
Public health emergencies can quickly provoke alarm and shock in the society, as well as generate high-impact online public opinion through network fermentation. Analyzing the generation mechanism of online public opinion in public health emergencies helps to explain its characteristics and laws. Based on information ecology theory, seven indicators from the four dimensions of information person, information, information technology, and information environment are extracted, and the analysis framework of public opinion impact of public health emergencies is constructed. Taking 40 cases from China as samples, fuzzy set qualitative comparative analysis (fsQCA) is used to investigate the generation path and mechanism of online public opinion impact in public health emergency. The results suggest that: information person and information technology are the core conditions for the generation of high-impact online public opinion, but the harm level contained in the information itself is not sensitive to the generation of public opinion impact; there are four generation paths and three types that drive the generation of high-impact online public opinion in public health emergencies. This work enriches the cognition of the causality of public opinion impact in public health emergencies from the perspective of configuration, and clearly shows which combination of variables leads to high-impact online public opinion, and helps to prevent and reduce the risk of public opinion.
PROBLEM TO BE SOLVED: To provide dental products capable of administering for enhancing bone/tooth growth.SOLUTION: The dental products are improved by dissolving, dispersing or coating a compound which promotes bone growth. Preferred compounds are disclosed peptide sequences containing 10 to 50 amino acids. The sequences are characterized by containing residual amino acids adjacent to an integrin-bonding motif (e.g. RGD sequence) and the RGD sequence of an extracellular phosphoglycoprotein of substrate cells. It is possible to make a preparation by dispersing the sequence in a tooth paste or an intraoral cleaning agent and administer for enhancing the growth of bone/tooth. By repeatedly using the dental product for a certain period, the health of teeth is improved well.
BACKGROUND: This study aimed to evaluate if neoadjuvant immune checkpoint inhibitor (ICI) plus chemotherapy (CT) reduced tumor recurrence after surgery than neoadjuvant CT alone in non-small cell lung cancer (NSCLC) patients with pathologic complete response (pCR).
METHODS: From January 1st 2019 to April 30th 2022, 16 NSCLC patients with pCR who received both neoadjuvant ICI and CT were designated as ICI/CT group. Another 8 patients, who received neoadjuvant CT alone, were designated as CT group. The tumor recurrence and patients' survival status were analyzed.
RESULTS: Squamous cell carcinoma was the predominant histology type in both groups. The CT group had higher percentage of patients who received adjuvant CT than the ICI/CT group (100% vs. 75%, p = 0.046). All patients had been followed up for at least 20 months. At 20 months after surgery, the ICI/CT group had a tumor recurrence rate of 6.25%, which was significantly lower than 37.5% recurrence rate of the CT group. One patient of the CT group died of gastrointestinal hemorrhage and severe anemia at 11 months after surgery, and no patient in the ICI/CT group died. During adjuvant therapy, the ICI/CT group had significantly lower risk of anemia (12.5% vs. 50%) than the CT group (p = 0.046).
CONCLUSION: The study found that in NSCLC patients with pCR, neoadjuvant ICI reduced tumor recurrence rate. This indicated that like in advanced stage NSCLC, the ICI might bring similar long-term anti-tumor effect in operable NSCLC patients.
PROBLEM TO BE SOLVED: To provide an oral composition having biofilm formation inhibitory action.SOLUTION: An oral composition comprises plant extract that is hot water extract of Brassica rapa var. perviridis, Brassica rapa var. laciniifolia, Brassica rapa var. laciniifolia subvar. oblanceolata, Raphanus sativus L. var. longipinnatus L.H.Bailey, Nasturtium officinale, Matteuccia struthiopteris (L.) Todaro, Aralia elata, or Mesembryanthemum crystallinum L.SELECTED DRAWING: Figure 2
Participants will attend 1st lab based session that will test cue-reactivity. Participant will be randomized to view either AR images, or in vivo items first. Order of presentation of items will also be randomized within the type (AR or in vivo).Session 1 should last under 1 hour.
Subjects will receive iNO for 4 hours, followed by standard respiratory support (SRS) for 4 hours. This pattern will be reversed the next day (SRS then iNO). on the following day, the pattern will be reversed back to iNO for 4 hours and SRS for 4 hrs.
After meeting the full eligibility requirement, participants will be randomized. Approximately 25 of the 51 participants will assigned to this arm of the study. Subjects in this arm will receive the placebo drug.
The device is a light and sound device that delivers light stimulation using light-emitting diodes (LED) and sound stimulation through a speaker, with a centrally-mounted tablet that plays videos for entertainment. The device will be positioned on an easel such that the tablet is eye level with the participant while they are sitting 5 feet away. The active device delivers light and sound at 40Hz rate.
In a 24 month oral carcinogenicity study in mice dosed with 10 mg/kg/day DRSP alone or 

1 + 0.01, 3 + 0.03 and 10 + 0.1 mg/kg/day of DRSP and EE, 0.1 to 2 times the exposure (AUC of DRSP) of women taking a contraceptive dose, there was an increase in carcinomas of the harderian gland in the group that received the high dose of DRSP alone. In a similar study in rats given 10 mg/kg/day DRSP alone or 0.3 + 0.003, 3 + 0.03 and 10 + 0.1 mg/kg/day DRSP and EE, 0.8 to 10 times the exposure of women taking a contraceptive dose, there was an increased incidence of benign and total (benign and malignant) adrenal gland pheochromocytomas in the group receiving the high dose of DRSP. Mutagenesis studies for DRSP were conducted in vivo and in vitro and no evidence of mutagenic activity was observed. [See Warnings and Precautions (5.3, 5.4)].

Long-term animal studies have not been conducted to evaluate the carcinogenic potential of levomefolate. Mutagenesis studies for levomefolate were conducted in vitro and in vivo and no evidence of mutagenic activity was observed.
Subjects who, at enrollment, have been on a TKI for 4 weeks or more will be monitored with the Sensus smartphone application, Fitbit Sense, RX Cap, and paper surveys. Visits will be at: Screening, Baseline, Week 1, and then every 8 weeks for 24 weeks.
OBJECTIVE: To construct and verify a risk prediction model for sleep disturbance in elderly patients with hypertension, aiming to offer guidance for sleep management in this demographic.
METHODS: A cohort of 6,708 elderly hypertensive patients from the NHANES database, spanning 2005 to 2018, met the inclusion criteria and were selected for this study. Participants were randomly assigned to a development group (n = 4,696) and a verification group (n = 2,012) in a 7:3 ratio. The occurrence of sleep disturbance was assessed across the subjects. Independent risk factors for sleep disturbance were analyzed using weighted multivariate logistic regression within the development group. A predictive model for sleep disturbance risk in elderly hypertensive patients was developed and verified using Stata 17.0. The model's predictive accuracy and stability were evaluated using the verification group's data.
RESULTS: Of the 6,708 subjects, 2,014 (30.02%) were identified with sleep disturbance, and the weighted prevalence of sleep disturbance among elderly hypertensive patients was 33.283%. Weighted multivariate logistic regression analysis in the development group revealed that six factors were independently associated with sleep disturbance: higher total depression scores, higher education level, asthma, overweight, arthritis, and work restriction (OR > 1 and P < 0.05). The area under the receiver operating characteristic (ROC) curve (AUC) for the nomogram prediction model was 0.709 in the development group and 0.707 in the verification group, indicating good discrimination ability. Brier scores for the nomogram model were 0.185 in the development group and 0.189 in the verification group, both below 0.25, suggesting good calibration. Decision Curve Analysis (DCA) determined that the nomogram's clinical net benefit was maximized when the threshold probability for sleep disturbance in elderly hypertensive patients was 0.13-0.67 in the development group and 0.14-0.61 in the verification group, highlighting the model's clinical utility.
LIMITATIONS: This study is not without its limitations, including issues with data collection, the absence of external validation, and the non-extrapolation of results.
CONCLUSION: The prevalence of sleep disturbance among elderly hypertensive patients stands at 33.283%. The nomogram model, based on identified risk factors for sleep disturbance in this population, has demonstrated good predictive efficiency and clinical relevance. It serves as a valuable tool to assist healthcare providers in identifying elderly hypertensive patients at high risk for sleep disturbance.